Laura Ramos-Petersen1, Christopher James Nester2, Andres Reinoso-Cobo3, Pilar Nieto-Gil4, Ana Belen Ortega-Avila3,5, Gabriel Gijon-Nogueron3,5. 1. Department Podiatry, Universidad Católica San Antonio de Murcia, 30107 Murcia, Spain. 2. School of Health & Society, University of Salford, Salford M5 4WT, UK. 3. Department Podiatry, University of Malaga, Arquitecto Francisco Penalosa 3, 29071 Malaga, Spain. 4. Department of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain. 5. Instituto de Investigación Biomedica de Malaga (IBIMA), 29071 Malaga, Spain.
Abstract
Background and objective: Ninety percent of patients with rheumatoid arthritis (RA) feel foot pain during the disease process. Pharmacological treatment of RA has a systematic effect on the body and includes: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. The objective of our review was to examine the impact of biologics on patients with RA 'foot. Methods and material: A systematic review of randomized control trials and observational studies that evaluated the efficacy of biologics against other pharmacological treatment, and included a foot outcome measure. The search covered MEDLINE Ovid, Pubmed, CINAHL, Cochrane Library, Evidence Search, and Web of Science. Risk of bias was evaluated using Cochrane guidance and the Newcastle Ottawa Scale adapted version. Results: A total of eight studies fully met the inclusion criteria: Three randomized control trials, and five observational studies were the basis of our review. A total sample of 1856 RA patients with RA treatment participated. The use of biologics was not associated as a risk factor for post-operative surgical site infection or delayed wound healing. The benefits of biologics, in terms of the disease evolution, were assessed using X-ray. Conclusion: Evidence suggests that the use of biologics is not a risk factor for post-operative surgical site infection or delayed wound healing. The use of biologics presents benefits in terms of the disease evolution assessed through X-ray.
Background and objective: Ninety percent of patients with rheumatoid arthritis (RA) feel foot pain during the disease process. Pharmacological treatment of RA has a systematic effect on the body and includes: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. The objective of our review was to examine the impact of biologics on patients with RA 'foot. Methods and material: A systematic review of randomized control trials and observational studies that evaluated the efficacy of biologics against other pharmacological treatment, and included a foot outcome measure. The search covered MEDLINE Ovid, Pubmed, CINAHL, Cochrane Library, Evidence Search, and Web of Science. Risk of bias was evaluated using Cochrane guidance and the Newcastle Ottawa Scale adapted version. Results: A total of eight studies fully met the inclusion criteria: Three randomized control trials, and five observational studies were the basis of our review. A total sample of 1856 RA patients with RA treatment participated. The use of biologics was not associated as a risk factor for post-operative surgical site infection or delayed wound healing. The benefits of biologics, in terms of the disease evolution, were assessed using X-ray. Conclusion: Evidence suggests that the use of biologics is not a risk factor for post-operative surgical site infection or delayed wound healing. The use of biologics presents benefits in terms of the disease evolution assessed through X-ray.
Authors: L R Lard; H Visser; I Speyer; I E vander Horst-Bruinsma; A H Zwinderman; F C Breedveld; J M Hazes Journal: Am J Med Date: 2001-10-15 Impact factor: 4.965
Authors: Simon J Otter; Kevin Lucas; Kate Springett; Ann Moore; Kevin Davies; Liz Cheek; Adam Young; Karen Walker-Bone Journal: Clin Rheumatol Date: 2009-12-08 Impact factor: 2.980
Authors: Anshuman P Malaviya; Jo Ledingham; Jill Bloxham; Aisla Bosworth; Maya Buch; Ernest Choy; Andrew Cope; John Isaacs; David Marshall; Gary Wright; Andrew J K Ostör Journal: Rheumatology (Oxford) Date: 2014-05-12 Impact factor: 7.580